drugset / Trial / NCT00676559
Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME Study
Phase 1
Withdrawn
Johns Hopkins University
Genentech, Inc. · collabJuvenile Diabetes Research Foundation · collab
RandomizedFactorialOpen-labelTreatment
Summary
This study looks to continue the study of anti-vegf therapy in patients with macular edema, and compare it to an anti-inflammatory therapy and a combined Anti-vegf and anti-inflammatory.
Timeline
- Start
- 2008-04
- Primary completion
- 2009-04
- Completion
- 2010-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |
| Subject | efalizumab | Monoclonal antibody | 1 mg/kg | Subcutaneous |